Markers of Response to Ovarian Cancer Chemotherapy Identified
the Cancer Therapy Advisor take:
Approximately 85% of women who are diagnosed with late-stage ovarian cancer die. In order to shrink the tumor, patients may undergo neoadjuvant chemotherapy before undergoing surgery. According to a study published in OncoTarget, high expression levels of the proteins HGF and cMET are found in women with ovarian cancer who did not benefit from chemotherapy prior to surgery.
Marisa Mariani, PhD, and colleagues looked at potential markers of chemotherapy resistance at the gene expression and microRNA level, and after that, they validated these markers of interest at the protein level.
The researchers studied tumor samples from patients with ovarian cancer after neoadjuvant chemotherapy and found numerous prevalent microRNAs, which revealed their ability to survive chemotherapy. MiR-193a-5p was the most significant microRNA, and the genes HGF and cMET target the microRNA significantly.
The highest levels of HGF and cMET were found in patients who relapsed after neoadjuvant chemotherapy while the lowest expression levels were found in patients who responded the best to treatment.
Senior author Christiano Ferlini, MD, PhD, said that when neoadjuvant chemotherapy has no effect, then it would be too late to perform surgery since the cancer has progressed. This discovery can prevent patients from undergoing unnecessary treatment.
Markers of Chemo Response Identified in Ovarian Cancer
Researchers from the Danbury Hospital Biomedical Research Institute have discovered that high expression levels of two proteins — HGF and c-MET — are present in women with ovarian cancer who did not benefit from undergoing tumor-shrinking chemotherapy therapy prior to having surgery to remove their tumor.
Marisa Mariani, PhD, of Danbury Hospital Biomedical Research Institute, and colleagues, who published their results in OncoTarget, made this discovery using a two-pronged approach that first explored possible markers of chemotherapy resistance at the microRNA and gene expression level, and then validated any markers of interest at the protein level.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer